Loading clinical trials...
Loading clinical trials...
An Open-Label, multicenter study in male pediatric patients with cerebral x-linked adrenoleukodystrophy (cald) to assess the effects of MIN-102 treatment on disease progression prior to human stem cel...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Minoryx Therapeutics, S.L.
NCT05819866 · Cerebral Adrenoleukodystrophy (cALD)
NCT03789721 · ALD (Adrenoleukodystrophy), Adrenoleukodystrophy, and more
NCT02698579 · Cerebral Adrenoleukodystrophy (CALD), Adrenoleukodystrophy (ALD), and more
NCT01896102 · Cerebral Adrenoleukodystrophy (CALD)
Hernan Amartino
Bueno Aires, Buenos Aires
CHU Kremlin Bicêtre
Paris
Universitätsmedizin Göttingen Georg-August-Universität
Göttingen
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions